ASLAN Pharmaceuticals (ASLN) Competitors

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Is ASLN or EYEN more profitable?

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. Eyenovia's return on equity of -1,108.24% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Eyenovia	-114,639.41%	-1,108.24%	-139.36%

Do analysts rate ASLN or EYEN?

Eyenovia has a consensus price target of $2.00, suggesting a potential downside of 18.03%. Given Eyenovia's stronger consensus rating and higher possible upside, analysts plainly believe Eyenovia is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Eyenovia	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more volatility & risk, ASLN or EYEN?

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Do insiders and institutionals believe in ASLN or EYEN?

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Eyenovia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor ASLN or EYEN?

ASLAN Pharmaceuticals received 26 more outperform votes than Eyenovia when rated by MarketBeat users. However, 64.21% of users gave Eyenovia an outperform vote while only 63.49% of users gave ASLAN Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ASLAN Pharmaceuticals	Outperform Votes 200 63.49%	Underperform Votes 115 36.51%
Eyenovia	Outperform Votes 174 64.21%	Underperform Votes 97 35.79%

Does the media prefer ASLN or EYEN?

In the previous week, Eyenovia had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Eyenovia and 0 mentions for ASLAN Pharmaceuticals. Eyenovia's average media sentiment score of 0.44 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Eyenovia is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Eyenovia	Neutral

Which has better valuation & earnings, ASLN or EYEN?

Eyenovia has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Eyenovia is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	-0.03
Eyenovia	$67.06K	104.89	-$27.26M	-$58.40	-0.04

Summary

Eyenovia beats ASLAN Pharmaceuticals on 9 of the 17 factors compared between the two stocks.